Evaluation of the Pharmacokinetics and Renal Excretion of Simeprevir in Subjects with Renal Impairment

BACKGROUND: Simeprevir is a N3/4 protease inhibitor approved for the treatment of hepatitis C virus (HCV) infection. HCV prevalence is higher in patients with chronic kidney disease compared with the general population; safe and efficacious therapies in renal impairment are needed. OBJECTIVES: To ev...

Descripción completa

Detalles Bibliográficos
Autores principales: Ouwerkerk-Mahadevan, Sivi, Beumont-Mauviel, Maria, Mortier, Steven, Peeters, Monika, Verloes, Rene, Truyers, Carla, Mannens, Geert, Wynant, Inneke, Simion, Alexandru
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer International Publishing 2015
Materias:
Original Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4561054/
https://www.ncbi.nlm.nih.gov/pubmed/26248593
http://dx.doi.org/10.1007/s40268-015-0101-0

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4561054/
https://www.ncbi.nlm.nih.gov/pubmed/26248593
http://dx.doi.org/10.1007/s40268-015-0101-0

Ejemplares similares